


PHARMACEUTICAL 2018

Dicerna Pharmaceuticals Inc Rank 110 of 342







Dicerna Pharmaceuticals Inc Rank 110 of 342

The relative strengths and weaknesses of Dicerna Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dicerna Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 114% points. The greatest weakness of Dicerna Pharmaceuticals Inc is the variable Net Income, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 162%, being 117% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	118,558
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,646
Liabilities, Non-Current	0
Other Assets	814
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	3,000
Other Net Income	539
Other Revenues	2,277
Property and Equipment	1,512
Research and Development	36,983
Selling, General and Administrative Expense	25,881

Output Variable	Value in 1000 USD
Assets	120,884
Liabilities	19,646
Expenses	62,864
Revenues	2,277
Stockholders Equity	101,238
Net Income	-60,048
Comprehensive Net Income	-60,048
Economic Capital Ratio	162%

